共 9 条
[1]
Metabolic derangem ent in ischemic heartdisease and its therapeutic control. Farrari R,Pepi P,Farrari F,etal. A m JCardiol . 1998
[2]
Trim etazidine european m ulticenter study versuspropranolol in stable angina pectoris:contribution of holterelectrocardiograph am bulatory monitoring. Detry JM,Leclercq PJ. The American Journal of Cardiology . 1995
[3]
Combination treatment with trim etazidineand diltiazem in stable angina pectoris. Manchanda SC,K rishnaswarni S. H eart . 1997
[4]
Effects of trimetazidineon heart rate variability and left ventricle systolic performance in patientswith coronary artery disease after percutaneous translum inal angioplasty. Birand A,Kudaiberdieva GZ,Batyraliev TA,et al. Angiology . 1997
[5]
Metabolic m anagem ent of ischem ic heart disease:clinical data with trimetazidine. Desideri A,Celegon L. American Journal of Chinese Medicine . 1998
[6]
Therapeutic value of a cardioprotectiveagent in patients with severe ischemic cardiom yopathy. Brottier L .Barat JL,Com be C,et al. European Heart Journal . 1990
[7]
DRUGS[P]. HIDAKA HIROYOSHI;TAKAGI MANABU;MATSUZAKI TAKUSHI.WO9964011A1,1999-12-16
[8]
Trim etazidine:Potential m echanism s of action in hypertrophiccardiomyopathy. D’Hahan N. Journal of Cardiovascular Pharmacology . 1999
[9]
Com bination therapy of trim etazidine with diltiazem in patients ofcoronary artery disease. Levy S. The American Journal of Cardiology . 1995